Copy
CANCER CLINICAL TRIALS NEWSLETTER
An Open-Label, Multicenter, Phase 1B Study of RP1 in Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma

This is a multicenter, open-label, study to investigate the safety and tolerability of RP1 for the treatment of advanced CSCC in up to 30 evaluable organ transplant recipients. RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly destroy tumors and generate an anti-tumor immune response. Patients will be dosed with RP1 by direct or ultrasound guided intra-tumoral injection into superficial, subcutaneous or nodal tumors. Efficacy will be measured by measuring adverse events, and the percentage of subjects experiencing organ allograft rejection. 

(RPL-003-19, IRB 2021-0032)
3510-RADCOMP
2017-6236
PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL
 

A221805
2020-1258

 
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
 
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!

 


GIVEHOPE and BSI Engineering Celebrate Ten Years of Driving Research

Cincinnati-based nonprofit GIVEHOPE and consulting firm BSI Engineering are celebrating a philanthropic partnership that has funded 13 pilot research projects at the University of Cincinnati Cancer Center. Together, GIVEHOPE and BSI have raised $800,000 to benefit pancreatic cancer research, education, prevention and awareness programs at the UC Cancer Center. 
Click Here to Visit the UC Newsroom
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
CANCER CLINICAL TRIALS NEWSLETTER
Questions?  Please call us at 513-584-7698, or email us!
Copyright © 2019, All rights reserved.

UC Cancer Center Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
Marcumma@ucmail.uc.edu






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA